News

DANBIO: Anti-TNFs Do Not Up Overall Cancer Risk in Arthritis


 

FROM THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY

DANBIO is financially supported by grants from the Danish Rheumatism Association and the Danish Cancer Society. Dr. Hetland has acted as a consultant to Roche, and has received grants and research support on behalf of DANBIO from Abbott, BMS, Centocor, Roche, Schering-Plough, UCB-Nordic, and Wyeth. Dr. Dreyer had no disclosures. Dr. Schett was not involved in the study.

Pages

Recommended Reading

Preop Ultrasound Unreliable in Melanoma Staging
MDedge Hematology and Oncology
FDA Okay Expected Soon for Melanoma Drug Ipilimumab
MDedge Hematology and Oncology
FDA: Ipilimumab Approved for Metastatic Melanoma
MDedge Hematology and Oncology
Once Again, Results Mixed for SN Biopsy in Melanoma
MDedge Hematology and Oncology
FDA Approves Peginterferon Alfa-2b for Melanoma
MDedge Hematology and Oncology
Thin vs. Thick Melanomas: Both Carry Same SLN Involvement Risk
MDedge Hematology and Oncology
Lymphatic Invasion Predicts Recurrence in Merkel Cell Cancer
MDedge Hematology and Oncology
Ipilimumab and Beyond: New Therapies Imminent in Melanoma
MDedge Hematology and Oncology
Serum Antibody Profiling in Melanoma
MDedge Hematology and Oncology
Ipilimumab for Metastatic Melanoma
MDedge Hematology and Oncology